As a result, genome alterations such as PIK3CA mutation and the loss of PTEN expression, which upregulates the PI3K pathway, can also promote estrogen-independent ER activation and render breast cancer cells resistant to endocrine therapy. This evidence concerns the gene PIK3CG and breast cancer.